

PEDIATRIC PRECLINICAL TESTING PROGRAM (PPTP)

EXECUTIVE SUMMARY

The NCI-supported Pediatric Preclinical Testing Program (PPTP) is a comprehensive program to systematically evaluate new agents against molecularly characterized childhood solid tumor and leukemia models. The PPTP is supported through an NCI research contract to Nationwide Children's Hospital (Columbus, OH) with Dr. Peter Houghton as the Principal Investigator. Testing occurs both at Nationwide and also at subcontract sites that have expertise in specific childhood cancers, including: Children's Hospital of Philadelphia (John Maris), Albert Einstein Medical Center (E. Anders Kolb & Richard Gorlick), Duke University (Stephen Keir & Henry Friedman), Texas Tech University Health Sciences Center (Patrick Reynolds), and Children's Cancer Institute Australia (Richard Lock).

The primary goal of the PPTP is to identify new agents that have the potential for significant activity when clinically evaluated against selected childhood cancers. The program is based on a substantial body of data showing that appropriate childhood cancer preclinical *in vivo* models can recapitulate the antitumor activity of known effective agents and can prospectively identify novel agents subsequently shown to have clinical activity against specific cancers of children and adolescents.

The PPTP systematically tests 10-12 agents or combinations of agents annually in *in vitro* and *in vivo* preclinical models of common childhood cancers. The PPTP seeks to test these agents near the time that they are entering phase 1 evaluation in adults with cancer and prior to their possible initial evaluation in children. Pharmacokinetic studies are performed to determine the systemic drug exposures associated with antitumor activity, which allows comparison between the drug exposures required for activity in the childhood cancer preclinical models and those achievable in humans. When appropriate for molecularly targeted agents, the degree of target modulation associated with antitumor activity is evaluated.

To facilitate interactions between pharmaceutical sponsors and the PPTP, NCI developed model material transfer agreements (MTAs) in collaboration with pharmaceutical sponsors and academic research centers. The provisions included in the model MTAs have been accepted by all of the PPTP institutions.

By facilitating development of a more reliable pediatric new agent prioritization process, the PPTP contributes to the goal of identifying more effective treatments for children with cancer. Additional information about the PPTP can be obtained from the [PPTP web site](#) or from the PPTP Project Officer:

Malcolm Smith, MD, PhD
Cancer Therapy Evaluation Program, NCI
6130 Executive Boulevard
Room 7025
Bethesda, MD 20892
Bus: 301-496-2522
E-mail: Malcolm.Smith@nih.gov

January 2013

RATIONALE FOR THE PEDIATRIC PRECLINICAL TESTING PROGRAM (PPTP)

Scores of new agents are in development as cancer therapeutics. Only a fraction of these new agents can be systematically evaluated in children, largely because of the limited number of children eligible for early phase clinical trials. How can childhood cancer researchers select from among all potential candidate agents those that should be moved into clinical evaluation in children? This selection process is critical to future progress in curing more children diagnosed with cancer, as selecting effective agents for clinical evaluation makes progress likely, while selecting ineffective agents almost certainly precludes progress.

The PPTP is necessary in part because current knowledge of the biology of childhood cancers is insufficient to make *a priori* valid predictions about the clinical relevance to childhood cancers of new agents that target widely expressed cellular components (e.g. microtubules, kinesins, topoisomerases, proteasomes, hsp90, etc.) and new agents that target broadly active signaling pathways (e.g., MAP kinase, AKT, apoptosis, and farnesylation-dependent pathways). A molecularly characterized preclinical panel is also a valuable resource for testing agents directed against tumor specific targets (e.g., oncogenic fusion proteins).

The PPTP builds upon research by Houghton and colleagues demonstrating the ability of preclinical testing using rhabdomyosarcoma and neuroblastoma xenografts to predict for activity of new agents in children with these cancers.(1-7) For example, as summarized in the table below, the activity of standard agents against rhabdomyosarcoma is mirrored by their level of activity in xenograft lines.(1)

Table 1
Sensitivity of rhabdomyosarcoma and colon adenocarcinoma xenografts to conventional cytotoxic agents

Agent/tumour type	Objective response rate (%) in the model	Objective response rate (%) in the clinic
<i>Rhabdomyosarcoma</i> ^a		
Vincristine	78	59
Cyclophosphamide	44	54
Actinomycin D	11	24
Doxorubicin	19	31
<i>Colon carcinoma</i>		
Vincristine	0	<10
Cyclophosphamide	0	<10
Actinomycin D	0	<10
Doxorubicin	0	<10
5-fluorouracil	17	15-20
Methyl CCNU	17	15-20


Subsequent work by Dr. Houghton in xenograft lines identified topoisomerase 1 inhibitors as active agents against rhabdomyosarcoma and neuroblastoma xenograft lines, a finding that was recapitulated when these agents were studied in the clinic against these diagnoses.(2-5) Similarly, Lock and colleagues have developed data indicating that NOD/SCID models of childhood acute lymphoblastic leukemia (ALL) provide an accurate representation of the human disease, both in terms of biological characteristics and in terms of response to therapy.(8;9) The PPTP is designed to extend these observations to other childhood cancer types and to a broader spectrum of anticancer agents. A listing of publications for agents tested to date by the PPTP is appended at the end of this document.

MOLECULAR CHARACTERIZATION OF THE PPTP XENOGRRAFT AND CELL LINES

The PPTP childhood tumor xenograft models have been characterized by gene expression arrays (cDNA and Affymetrix) as well as by tissue arrays (prepared by Dr. Stephen Hewitt, NCI). These studies were initiated as part of the NCI/CTEP Pediatric Oncology Preclinical Protein-Tissue Array Project (POPP-TAP) initiative and were continued in conjunction with the PPTP. The Affymetrix arrays are publicly available at the PPTP website (<http://pptp.ncihresearch.org/data.html>).

Results from gene expression studies are informative as to whether specific preclinical models have characteristics of their tumors of origin (i.e. clustering with the appropriate clinical histology). The preclinical models used by the PPTP meet the criteria of having gene expression profiles that are highly related to expression profiles of clinical specimens for the same diagnoses. (10; 11)

The gene expression profiles may also be useful in evaluating the expression of potential therapeutic targets in specific xenograft and cell lines and in identifying associations between expression patterns and agent activity. As an example, the figure below demonstrates high level expression of insulin-like growth factor 2 (IGF2) for rhabdomyosarcoma and Wilms tumor lines, as well as the expected expression of PHOX2B (a homeobox transcription factor that functions in the differentiation of the sympatho-adrenal lineage) in neuroblastoma lines.



SNP analysis using the Affymetrix GeneChip Human Mapping array has been performed as a quality control measure and for use in characterizing the PPTP lines for regions of LOH and for chromosome copy number abnormalities. The chromosome copy number abnormalities exhibited by the PPTP *in vitro* and *in vivo* panels correspond to those present in clinical specimens from the corresponding diagnoses. (11)

TESTING AGENTS THROUGH THE PPTP


Several standard chemotherapy agents have been tested through the PPTP during its first year of operations in order to calibrate the PPTP tumor panels using agents of known clinical activity for specific tumor types. Two standard agents that have clinical utility against childhood cancer, cyclophosphamide and vincristine, were both identified as highly active in the PPTP screen.(12)

New agents are ideally tested by the PPTP near the time that they are entering phase 1 evaluation in adults with cancer and prior to their possible initial evaluation in children. For both new agents and standard agents that show antitumor activity against PPTP childhood cancer models, pharmacokinetic studies are performed to determine the serum drug levels and systemic drug exposures associated with antitumor activity. For selected molecularly targeted agents, the PPTP evaluates whether target inhibition/modulation is achieved by the agent under the test conditions and whether this modulation is associated with antitumor activity. Results from the preclinical testing program will be correlated with the clinical activity and the pharmacokinetic profile of the tested agents in children to assess the predictive capabilities of the PPTP's childhood cancer panels and the animal models.

Testing for different tumor panels occurs both at Nationwide and also at subcontract sites that have expertise in specific childhood cancers as shown in the table below:

Site	Tumor Types Tested
Nationwide Children's Hospital	Rhabdomyosarcoma, Ewing sarcoma, Wilms tumor, Rhaboid tumor, Medulloblastoma, Ependymoma
Children's Hospital of Philadelphia	Neuroblastoma
Children's Cancer Institute Australia	Acute lymphoblastic leukemia
Duke University	High-grade gliomas
Albert Einstein Medical Center	Osteosarcoma
Texas Tech University	<i>In vitro</i> panel

The operational schema for the PPTP shown in the figure below was developed following several meetings between CTEP/NCI and interested childhood cancer investigators and has been described in detail in the PPTP's first testing report describing the evaluation of the standard agents cyclophosphamide and vincristine.(12;13)



Stage 1 Testing: The agent is tested at its Maximum Tolerated Dose (MTD) in test animals to identify those agents that have significant antitumor activity against one or more of the PPTP's preclinical models. Agents entering Stage 1 testing are evaluated against multiple tumor panels, each panel representing a specific histiotype and encompassing some of the genetic diversity of the disease. A full listing of the xenograft lines included in the PPTP's *in vivo* tumor panels is provided in Table 1. The PPTP has established panels for Stage 1 testing for sarcomas [rhabdomyosarcoma (n=6), Ewing sarcoma (n=5), and osteosarcoma (n=6)], neuroblastoma (n=6), acute lymphoblastic leukemia (n=8), glioblastoma (n=4), ependymoma (n=2), medulloblastoma (n=4), Wilms tumor (n=3), and rhabdoid tumor (n=3). Thus, each agent is evaluated in Stage 1 against 47 tumor models to determine the agent's level and spectrum of activity when it is administered at its MTD.

Stage 2 Testing: Those agents that demonstrate sufficient activity (either broad-spectrum or histiotype specific) in Stage 1 testing are considered for Stage 2 testing. Detailed plans for Stage 2 testing are prepared following a comprehensive evaluation of the Stage 1 results by NCI, PPTP researchers, and the pharmaceutical sponsor for the agent. Additional drug supply is requested from the sponsor for the studies to which both parties agree. A key component of Stage 2 testing is determining dose response relationships using tumor models in which activity was observed in Stage 1. Stage 2 testing generally includes detailed pharmacokinetic and pharmacodynamic studies to establish the relationship between systemic exposure and antitumor activity. When appropriate for molecularly targeted agents, the degree of target modulation associated with antitumor activity is evaluated. Stage 2 testing may also include evaluation in appropriate secondary models (e.g., orthotopically implanted rhabdomyosarcoma and glioblastoma, and disseminated models of neuroblastoma) to confirm or refute results obtained using subcutaneous tumors. In addition, the

PPTP has access to selected genetically engineered mouse models that may be utilized when relevant during Stage 2 testing.

In Vitro Testing: Selected agents are screened against a panel of 23 cell lines. The cell lines, representing each of the tumor types in the *in vivo* screening panels, are listed in Table 2. Testing is done in the laboratory of Dr. Patrick Reynolds using the DIMSCAN methodology developed in his laboratory. DIMSCAN is a semi-automatic digital image microscopy system for measuring relative cell numbers in tissue culture plates. Cytotoxicity assays measured by DIMSCAN using fluorescein diacetate, a dye accumulating selectively in viable cells, can achieve a 4 log dynamic range at 4 to 7 days, and correlate with colony forming assays. In selected cases, only following agreement with the supplier of the agent, combination studies can be undertaken to determine drug interactions that may be synergistic or antagonistic.

Drug supply and distribution: Sufficient agent is initially supplied to the PPTP to complete Stage 1 testing. Depending upon the results of the Stage 1 testing, a plan for Stage 2 testing is developed and the drug supply required for these additional studies is requested. For Stage 1 testing agents are tested at their MTD. Assuming the average test animal is .02 kg, then the total approximate drug requirement for phase 1 testing can be calculated as the product of the first 6 items in the table below, which provides the total drug requirement for an agent for which 1 mg/kg was the total dose per course and for which two courses were administered.

Dose per course (mg/kg)	1
# Lines	47
# Animals/Line	10
# Courses	2
Animal Weight (kg)	0.02
Dispensing/Reconstitution Factor	1.5 - 2
Drug Required (mg) per 1 mg/kg per course dose	28.2 - 37.6

Agents obtained from pharmaceutical sponsors are supplied to the PPTP Operations Center at Nationwide, which then distributes agents in a blinded fashion to sites for testing. Complete instructions for drug storage, formulation and administration are provided to sites by the PPTP Operations Center.

SUBMISSION/SELECTION OF AGENTS FOR EVALUATION THROUGH THE PPTP

Agents are selected for PPTP evaluation by the Project Officer, who is advised by the NCI Pediatric Drug Development Group (PedDDG). The PedDDG includes representation from the Investigational Drug Branch (CTEP), the Clinical Investigations Branch (CTEP), the Regulatory Affairs Branch (CTEP), the Developmental Therapeutics Program, and the Pediatric Oncology Branch, as well as selected PPTP researchers. Its expertise encompasses preclinical drug development, early phase adult cancer drug development, regulatory and intellectual property issues related to preclinical testing, and pediatric oncology drug development. The PedDDG advises the PPTP Project Officer on all aspects of PPTP performance, including:

- Technical issues related to *in vitro* and *in vivo* testing,
- Regulatory and intellectual property issues related to obtaining new agents for testing,
- Identification of candidate agents for the PPTP to consider for testing, and
- Prioritization of agents for PPTP testing.

Approval of new agents for testing through the PPTP will be based on a number of factors, which are briefly described below:

- The agent should generally be one for which clinical testing in children is considered a potential priority, with testing able to begin within 12-24 months. Satisfactorily addressing this criterion will generally imply an active development plan for the agent for adult cancers and a willingness to consider pediatric evaluations of the agent.
- The agent should have plausible relevance to the treatment of childhood cancers, based on current understanding of the mechanism of action of the agent and current understanding of the biology of childhood cancers.
- Agents with molecular targets or mechanisms of action that have not been previously addressed by the PPTP will be prioritized higher than agents whose molecular targets have previously been addressed by the PPTP.
- Most agents selected for testing will have undergone extensive prior testing against adult preclinical cancer models. The pharmaceutical sponsor needs to be able to provide information based on this prior testing concerning drug formulation and optimal schedule/dosing to PPTP investigators so that a testing plan for the agent can be developed.
- Quantity of agent available for testing. The availability of sufficient quantity of agent for testing against the entire PPTP panel will favor one agent over a similar agent addressing the same target for which less agent is available for testing.

Pharmaceutical companies and cancer researchers wishing to nominate an agent(s) for evaluation by the PPTP should contact the NCI Project Officer. For agents that pharmaceutical companies wish to propose for PPTP testing, confidentiality agreements are prepared as necessary to allow provision of adequate information to NCI to allow a decision to be made about the appropriateness of evaluating the agent through the PPTP. Applications for PedDDG review can be either prepared by the pharmaceutical sponsor or by the NCI Project Officer (using information provided by the pharmaceutical sponsor). Applications (excluding appendices) should not exceed 10 pages in length and should address the following items:

- *Background Information:* sufficient information to identify and clarify the scientific and medical context from which the opportunity emerges.
- *Preclinical molecular target studies:* Sufficient information should be provided to document the degree of specificity of the agent for its claimed molecular target(s).
- *Preclinical in Vitro Studies:* Data from both single agent *in vitro* studies and combination *in vitro* studies, if performed, should be provided.
- *Preclinical in Vivo Studies:* Available data concerning the *in vivo* anticancer activity of the agent should be provided. In general, appropriate agent administration schedules for demonstrating anti-cancer activity and the maximum tolerated doses for these schedules should be known at the time that an agent is proposed for PPTP testing. For most agents, these data will likely be primarily taken from adult cancer preclinical models, but data from pediatric models should be provided as well when available. Data from both single agent *in vivo* studies and combination *in vivo* studies, if performed, should be provided.
- *Preclinical Pharmacokinetics:* Of particular interest is the availability of pharmacokinetic data from preclinical models used to demonstrate efficacy.
- *Commitment to Clinical Development:* Priority is given to studying agents that are entering adult clinical evaluation and that may have potential applicability in the childhood cancer setting. Information concerning the current status of clinical development of the agent should be provided, along with any plans for potential pediatric evaluations of the agent.
- *Additional Support:* Any support that the agent sponsor can provide towards the PPTP evaluation of the agent should be described, including performance of laboratory testing for pharmacokinetic or pharmacodynamic studies (e.g., testing to document modulation of the agent's target in tumor tissue).
- *Intellectual Property:* The application should indicate the willingness of the sponsor to negotiate Material Transfer Agreements (MTAs) with NCI based on the model MTAs that have been developed by NCI for the PPTP. These MTAs were developed by NCI in collaboration with pharmaceutical sponsors and academic research centers. The provisions included in the model MTAs have been accepted by all of the PPTP institutions.
- *Quantity of Agent Available:* The quantity of agent available for testing should be provided. For reference, the PPTP *in vivo* testing program contains 47 xenograft lines, and Stage I testing at the MTD for two courses across the entire panel requires approximately 28.2-37.6 mg of agent for every 1 mg/kg of agent administered per course.
- *Appendices:*
 - o Background preprints or reprints as appropriate.
 - o Detailed description of the formulation of the agent (and its preparation) to be used for *in vitro* and *in vivo* testing.

MATERIAL TRANSFER AGREEMENTS AND INTELLECTUAL PROPERTY PROVISIONS AND DISSEMINATION OF PPTP TEST RESULTS

Model Material Transfer Agreements (MTA) have been developed by NCI in collaboration with pharmaceutical sponsors and academic research centers. The provisions included in the model MTAs have been accepted by all of the PPTP institutions. NCI uses the model MTA to execute MTAs with those pharmaceutical companies providing agents for testing. NCI then executes MTAs with each of the PPTP institutions to allow provision of agents to the institutions for testing. The model MTA is available at the [PPTP website](#).

The primary objective of the PPTP is to develop preclinical data that will be useful to childhood cancer researchers in prioritizing new agents for clinical evaluation. Hence, it is essential that these data be made available to researchers in an expeditious manner. The PPTP's primary mechanisms for disseminating information is through peer-reviewed scientific journals and through presentation of data and results at academic symposia or similar professional meetings. As specified in the model MTA, such manuscripts may be submitted for publication only after the pharmaceutical sponsor has had forty-five days to review the proposed disclosure to determine if it includes any confidential or patentable information. Abstracts must be provided to the pharmaceutical sponsor in sufficient time to allow at least seven days to review any planned submission. In order to expedite publication of test results, the PPTP utilizes a manuscript template to facilitate rapid development of manuscripts upon completion of testing and analysis of test results.

SUMMARY

The PPTP is the first comprehensive effort to systematically test anticancer agents against a broad range of childhood cancer preclinical models, and it complements similar efforts for adult cancers that are supported by NCI and by pharmaceutical companies. The NCI-supported PPTP is a comprehensive program to systematically evaluate new agents against childhood solid tumor and leukemia models. The program is based on a substantial body of data showing that appropriate childhood cancer preclinical *in vivo* models can recapitulate the antitumor activity of known effective agents and can prospectively identify novel agents that are subsequently shown to have clinical activity against specific cancers of children and adolescents. By facilitating development of a more reliable pediatric new agent prioritization process, the PPTP contributes to the goal of identifying more effective treatments for children with cancer.

FOR MORE INFORMATION CONTACT:

Malcolm Smith, MD, PhD
Assoc Branch Chief, Pediatrics
Cancer Therapy Evaluation Program, NCI
6130 Executive Boulevard
Room 7025
Bethesda, MD 20892
Bus: 301-496-2522
E-mail: Malcolm.Smith@nih.gov

Reference List

- (1) Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. *Eur J Cancer* 2004 May; 40(6):837-44.
- (2) Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. *J Clin Oncol* 1999 Jun; 17(6):1815-24.
- (3) Thompson J, George EO, Poquette CA, Cheshire PJ, Richmond LB, de Graaf SS, et al. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. *Clin Cancer Res* 1999 Nov; 5(11):3617-31.
- (4) Zamboni WC, Stewart CF, Thompson J, Santana VM, Cheshire PJ, Richmond LB, et al. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts [see comments]. *J Natl Cancer Inst* 1998 Apr 1; 90(7):505-11.
- (5) Houghton PJ, Cheshire PJ, Hallman JC, Bissery MC, Mathieu-Boue A, Houghton JA. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. *Cancer Res* 1993 Jun 15; 53(12):2823-9.
- (6) Wagner LM, Crews KR, Iacono LC, Houghton PJ, Fuller CE, McCarville MB, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. *Clin Cancer Res* 2004 Mar 1; 10(3):840-8.
- (7) Houghton PJ, Stewart CF, Cheshire PJ, Richmond LB, Kirstein MN, Poquette CA, et al. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. *Clin Cancer Res* 2000 Oct; 6(10):4110-8.
- (8) Bachmann PS, Gorman R, MacKenzie KL, Lutze-Mann L, Lock RB. Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor. *Blood* 2004 Nov 30.
- (9) Lock RB, Liem N, Farnsworth ML, Milross CG, Xue C, Tajbakhsh M, et al. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. *Blood* 2002 Jun 1; 99(11):4100-8.
- (10) Whiteford CC, Bilke S, Greer BT, Greer BT, Chen Q, Braunschweig TA, et al. Credentialing Preclinical Pediatric Xenograft Models Using Gene Expression and Tissue Microarray Analysis. *Cancer Res* 2007 Jan 1; 67(1):32-40.
- (11) Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, et al. Molecular characterization of the Pediatric Preclinical Testing Panel. *Clin Cancer Res* 2008 Jul 15; 14(14):4572-83.
- (12) Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, et al. The Pediatric Preclinical Testing Program: description of models and early testing results. *Pediatr Blood Cancer* 2007 Dec; 49(7):928-40.
- (13) Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, et al. Testing of new agents in childhood cancer preclinical models: meeting summary. *Clin Cancer Res* 2002 Dec; 8(12):3646-57

Table 1. Pediatric Preclinical Testing Program *in Vivo* Panel

NAME	DIAGNOSIS	PANEL	STATUS	PROPERTIES
KT-10	Wilms tumor	Primary	Diagnosis	Favorable Histology
KT-11	Wilms tumor	Primary	Diagnosis	Favorable Histology
KT-13	Wilms tumor	Primary	Diagnosis	Diffuse Anaplastic
KT-5	Wilms tumor	Secondary		Nuclear Unrest
BT-29	Rhabdoid tumor	Primary	Diagnosis	
KT-14	Rhabdoid tumor	Primary	Relapse	
KT-16	Rhabdoid tumor	Primary	Relapse	
KT-12	Rhabdoid tumor	Secondary	Diagnosis	
CHLA258*	Ewing sarcoma	Primary		
EW5	Ewing sarcoma	Primary	Diagnosis	
EW8(Rh1)	Ewing sarcoma	Primary	Diagnosis	
SK-NEP-1**	Ewing sarcoma	Primary	Relapse	
TC-71	Ewing sarcoma	Primary	Relapse	
Rh10	Rhabdomyosarcoma	Primary	Relapse	Alveolar
Rh18*	Rhabdomyosarcoma	Primary	Diagnosis	Embryonal
Rh28	Rhabdomyosarcoma	Primary	Diagnosis	Alveolar
Rh30*	Rhabdomyosarcoma	Primary	Diagnosis	Alveolar
Rh30R	Rhabdomyosarcoma	Primary	Relapse	Alveolar
Rh41*	Rhabdomyosarcoma	Primary	Relapse	Alveolar
Rh36	Rhabdomyosarcoma	Secondary	Relapse	Embryonal
Rh65	Rhabdomyosarcoma	Secondary	Relapse	Alveolar
OS-1	Osteosarcoma	Primary	Diagnosis	
OS-2	Osteosarcoma	Primary	Diagnosis	
OS-9	Osteosarcoma	Primary		
OS-17	Osteosarcoma	Primary	Diagnosis	
OS-31	Osteosarcoma	Primary		
OS-33	Osteosarcoma	Primary		
OS-29	Osteosarcoma	Secondary		
BT-36	Ependymoma	Primary	Diagnosis	
BT-41	Ependymoma	Primary	Relapse	
BT-44	Ependymoma	Secondary		
BT-54	Ependymoma	Secondary	Relapse	
BT-28	Medulloblastoma	Primary	Diagnosis	
BT-45	Medulloblastoma	Primary	Diagnosis	
BT-46	Medulloblastoma	Primary	Diagnosis	
BT-50	Medulloblastoma	Primary	Diagnosis	
D456	Glioblastoma	Primary	Diagnosis	
D645	Glioblastoma	Primary	Diagnosis	
SJ-BT39	Glioblastoma	Primary	Relapse	
SJ-GBM2*	Glioblastoma	Primary	Relapse	
D212	Glioblastoma	Secondary	Diagnosis	
SJ-BT56	Glioblastoma	Secondary	Relapse	

NAME	DIAGNOSIS	PANEL	STATUS	PROPERTIES
CHLA-79	Neuroblastoma	Primary	Relapse	Non MycN amp
NB-1643*	Neuroblastoma	Primary	Diagnosis	MycN amp
NB-1691	Neuroblastoma	Primary	Relapse	MycN amp
NB-1771	Neuroblastoma	Primary	Diagnosis	MycN amp
NB-EBc1*	Neuroblastoma	Primary	Relapse	Non MycN amp
NB-SD	Neuroblastoma	Primary	Relapse	MycN amp
NB-1382	Neuroblastoma	Secondary	Relapse	MycN amp
SK-N-AS	Neuroblastoma	Secondary	Relapse	Non MycN amp
ALL-2	ALL	Primary	Relapse	B-precursor
ALL-4	ALL	Primary	Diagnosis	B-precursor (Ph+)
ALL-7	ALL	Primary	Diagnosis	B-precursor
ALL-8	ALL	Primary	Relapse	T-cell ALL
ALL-17	ALL	Primary	Diagnosis	B-precursor
ALL-19	ALL	Primary	Relapse	B-precursor
ALL-31	ALL	Primary	Diagnosis	T-cell ALL
MLL-7	ALL	Primary	--	MLL rearranged ALL
ALL-3	ALL	Secondary	Diagnosis	B-precursor
ALL-10	ALL	Secondary	Diagnosis	B-precursor
ALL-11	ALL	Secondary	Diagnosis	B-precursor
ALL-16	ALL	Secondary	Diagnosis	T-cell ALL
ALL-27	ALL	Secondary	Diagnosis	T-cell ALL
ALL-29	ALL	Secondary	Diagnosis	T-cell ALL
ALL-30	ALL	Secondary	Diagnosis	T-cell ALL
ALL-31	ALL	Secondary	Diagnosis	T-cell ALL
ALL-32	ALL	Secondary	Relapse	T-cell ALL
ALL-33	ALL	Secondary	Diagnosis	T-cell ALL
MLL-1	ALL	Secondary	--	MLL rearranged ALL
MLL-2	ALL	Secondary	--	MLL rearranged ALL
MLL-3	ALL	Secondary	--	MLL rearranged ALL
MLL-5	ALL	Secondary	Diagnosis	MLL rearranged ALL
MLL-6	ALL	Secondary	--	MLL rearranged ALL
MLL-8	ALL	Secondary	--	MLL rearranged ALL
MLL-14	ALL	Secondary	--	MLL rearranged ALL

*Line also in *in vitro* panel

**Previously considered anaplastic Wilms tumor, but confirmed to be Ewing family tumor based on EWS-ETS gene fusion transcripts

Table 2: Pediatric Preclinical Testing Program *in Vitro* Panel:

Name	Diagnosis	Panel
RD	Rhabdomyosarcoma	Primary
Rh41*	Rhabdomyosarcoma	Primary
Rh18*	Rhabdomyosarcoma	Primary
Rh30*	Rhabdomyosarcoma	Primary
BT-12	Rhabdoid	Primary
CHLA-266	Rhabdoid	Primary
TC-71	Ewing sarcoma	Primary
CHLA-9	Ewing sarcoma	Primary
CHLA-10	Ewing sarcoma	Primary
CHLA-258	Ewing sarcoma	Primary
SJ-GBM2*	Glioblastoma	Primary
NB-1643*	Neuroblastoma	Primary
NB-EBc1*	Neuroblastoma	Primary
CHLA-90	Neuroblastoma	Primary
CHLA-136	Neuroblastoma	Primary
NALM-6	Pre-B cell ALL	Primary
COG-LL-317	T-cell ALL	Primary
RS4;11	Pre-B cell ALL	Primary
MOLT-4	T-cell ALL	Primary
CCRF-CEM	T-cell ALL	Primary
Kasumi-1	AML	Primary
Karpas-299	Anaplastic Large Cell Lymphoma	Primary
Ramos	Burkitt's Lymphoma	Primary
CHLA-122	Neuroblastoma	Secondary
CHLA-119	Neuroblastoma	Secondary
SUDHL-1	Anaplastic Large Cell Lymphoma	Secondary
MV-4-11	AML	Secondary

*Line also in *in vivo* panel.

PPTP Publications:

1. Houghton PJ, Morton CL, Tucker C, et al. The Pediatric Preclinical Testing Program: description of models and early testing results. *Pediatr Blood Cancer* 2007;49(7):928-940.
2. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor **rapamycin** by the Pediatric Preclinical Testing Program. *Pediatr Blood Cancer* 2008;50(4):799-805.
3. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the proteasome inhibitor **bortezomib** by the Pediatric Preclinical Testing Program. *Pediatr Blood Cancer* 2008;50(1):37-45.
4. Keir ST, Morton CL, Billups C, et al. Initial testing of **VNP40101M (Cloretazine)** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2008;51(3):439-441.
5. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of a monoclonal antibody (**SCH 717454**) against the IGF-1 receptor by the Pediatric Preclinical Testing Program. *Pediatr Blood Cancer* 2008;50(6):1190-1197.
6. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing of **dasatinib** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2008;50(6):1198-1206.
7. Lock R, Carol H, Houghton PJ, et al. Initial testing (stage 1) of the BH3 mimetic **ABT-263** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2008;50(6):1181-1189.
8. Maris JM, Courtright J, Houghton PJ, et al. Initial testing of the VEGFR inhibitor **AZD2171** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2008;50(3):581-587.
9. Maris JM, Courtright J, Houghton PJ, et al. Initial testing (stage 1) of **sunitinib** by the Pediatric Preclinical Testing Program. *Pediatr Blood Cancer* 2008;51(1):42-48.
10. Smith MA, Morton CL, Phelps DA, et al. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor **alvespimycin (17-DMAG, KOS-1022)** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2008;51(1):34-41.
11. Tajbakhsh M, Houghton PJ, Morton CL, et al. Initial testing of **cisplatin** by the Pediatric Preclinical Testing Program. *Pediatr Blood Cancer* 2008;50(5):992-1000.
12. Carol H, Lock R, Houghton PJ, et al. Initial testing (stage 1) of the kinesin spindle protein inhibitor **ispinesib** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2009;53(7):1255-1263.
13. Gorlick R, Kolb EA, Houghton PJ, et al. Initial testing (stage 1) of **lapatinib** by the Pediatric Preclinical Testing Program. *Pediatr Blood Cancer* 2009;53(4):594-598.
14. Keshelava N, Houghton PJ, Morton CL, et al. Initial testing (stage 1) of **vorinostat (SAHA)** by the Pediatric Preclinical Testing Program. *Pediatr Blood Cancer* 2009;53(3):505-508.
15. Carol H, Houghton PJ, Morton CL, et al. Initial testing of **topotecan** by the Pediatric Preclinical Testing Program. *Pediatr Blood Cancer* 2010;54(5):707-715.
16. Carol H, Morton CL, Gorlick R, et al. Initial testing (stage 1) of the Akt inhibitor **GSK690693** by the Pediatric Preclinical Testing Program. *Pediatr Blood Cancer* 2010;55(7):1329-1337.
17. Houghton PJ, Morton CL, Gorlick R, et al. Initial testing of a monoclonal antibody (**IMC-A12**) against IGF-1R by the Pediatric Preclinical Testing Program. *Pediatr Blood Cancer* 2010;54(7):921-926.

18. Houghton PJ, Morton CL, Kang M, et al. Evaluation of **cytarabine** against Ewing sarcoma xenografts by the Pediatric Preclinical Testing Program. *Pediatr Blood Cancer* 2010;55(6):1224-1226.
19. Keir ST, Maris JM, Lock R, et al. Initial testing (stage 1) of the multi-targeted kinase inhibitor **sorafenib** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2010;55(6):1126-1133.
20. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of **AZD6244** (ARRY-142886) by the Pediatric Preclinical Testing Program. *Pediatr Blood Cancer* 2010;55(4):668-677.
21. Maris JM, Morton CL, Gorlick R, et al. Initial testing of the aurora kinase A inhibitor **MLN8237** by the Pediatric Preclinical Testing Program (PPTP). *Pediatr Blood Cancer* 2010;55(1):26-34.
22. Morton CL, Houghton PJ, Kolb EA, et al. Initial testing of the replication competent **Seneca Valley virus (NTX-010)** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2010;55(2):295-303.
23. Smith MA, Morton CL, Kolb EA, et al. Initial testing (stage 1) of **mapatumumab (HGS-ETR1)** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2010;54(2):307-310.
24. Gorlick R, Maris JM, Houghton PJ, et al. Testing of the Akt/PKB inhibitor **MK-2206** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2011.
25. Houghton PJ, Lock R, Carol H, et al. Initial testing of the hypoxia-activated prodrug **PR-104** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2011;57(3):443-453.
26. Kang MH, Smith MA, Morton CL, et al. National Cancer Institute Pediatric Preclinical Testing Program: Model description for in vitro cytotoxicity testing. *Pediatr Blood Cancer* 2011;56(2):239-249.
27. Kolb EA, Gorlick R, Lock R, et al. Initial testing (stage 1) of the IGF-1 receptor inhibitor **BMS-754807** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2011;56(4):595-603.
28. Lock RB, Carol H, Morton CL, et al. Initial testing of the CENP-E inhibitor **GSK923295A** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2011.
29. Reynolds CP, Kang MH, Keir ST, et al. Initial testing of **lenalidomide** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2011;57(4):606-611.
30. Smith MA, Maris JM, Lock R, et al. Initial testing (stage 1) of the polyamine analog **PG11047** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2011;57(2):268-274.
31. Batra V, Maris JM, Kang MH, et al. Initial testing (stage 1) of **SGI-1776**, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2012;59(4):749-752.
32. Carol H, Reynolds CP, Kang MH, et al. Initial testing of the MDM2 inhibitor **RG7112** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2012;Epub 2012/2007/2004.
33. Gorlick R, Kolb EA, Houghton PJ, et al. Initial testing (stage 1) of the cyclin dependent kinase inhibitor **SCH 727965 (dinaciclib)** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2012.
34. Gorlick R, Maris JM, Houghton PJ, et al. Testing of the Akt/PKB inhibitor **MK-2206** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2012;59(3):518-524.
35. Houghton PJ, Gorlick R, Kolb EA, et al. Initial testing (stage 1) of the mTOR kinase inhibitor **AZD8055** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2012;58(2):191-199.

36. Houghton PJ, Kang MH, Reynolds CP, et al. Initial testing (stage 1) of **LCL161**, a SMAC mimetic, by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2012;58(4):636-639.
37. Houghton PJ, Lock R, Carol H, et al. Testing of the topoisomerase 1 inhibitor **Genz-644282** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2012;58(2):200-209.
38. Kang MH, Reynolds CP, Houghton PJ, et al. Initial testing (Stage 1) of **AT13387**, an HSP90 inhibitor, by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2012;59(1):185-188.
39. Keir ST, Morton CL, Wu J, et al. Initial testing of the multitargeted kinase inhibitor **pazopanib** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2012;59(3):586-588.
40. Kolb EA, Gorlick R, Keir ST, et al. Initial testing (stage 1) by the pediatric preclinical testing program of **RO4929097**, a gamma-secretase inhibitor targeting notch signaling. *Pediatr Blood Cancer* 2012;58(5):815-818.
41. Kolb EA, Gorlick R, Maris JM, et al. Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody **IMC-A12 with rapamycin** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2012;58(5):729-735.
42. Lock RB, Carol H, Morton CL, et al. Initial testing of the CENP-E inhibitor **GSK923295A** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2012;58(6):916-923.
43. Morton CL, Maris JM, Keir ST, et al. Combination testing of **cediranib (AZD2171)** against childhood cancer models by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2012;58(4):566-571.
44. Reynolds CP, Kang MH, Carol H, et al. Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, **SAR245408 (XL147)** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2012.
45. Smith MA, Gorlick R, Kolb EA, et al. Initial testing of **JNJ-26854165** (Serdemetan) by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2012;59(2):329-332.
46. Smith MA, Kang MH, Reynolds CP, et al. Evaluation of **arsenic trioxide** by the pediatric preclinical testing program with a focus on Ewing sarcoma. *Pediatr Blood Cancer* 2012;59(4):753-755.
47. Smith MA, Maris JM, Gorlick R, et al. Initial testing of the investigational NEDD8-activating enzyme inhibitor **MLN4924** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2012;59(2):246-253.
48. Keir ST, Maris JM, Reynolds CP, et al. Initial testing (stage 1) of **temozolomide** by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2013:Epub 01/22/2013.
49. Lock RB, Carol H, Maris JM, et al. Initial testing (stage 1) of **ganetespib**, an Hsp90 inhibitor, by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2013.